• Llorente Bonaga: Merck & Co. Inc., Regulatory CMC
  • Peter Capella: Director, FDA, CDER/OPQ/OLDP/Division of Immediate and Modified Release Drug Products II
  • Olivier Dirat: Pfizer R&D UK Ltd, Advisory Office in Reg CMC
  • Deniz Erdemir: Bristol Myers Squibb, Material Engineering and Engineering (Drub Product Development)
  • Steven Ferguson: UCD, Lead for Manufacturing Team for SSPC
  • Stephen W. Hoag: University of Maryland, Prof. School of Pharmacy, Pharmaceutical Sciences
  • Ephrem Hunde: FDA, Office of Pharmaceutical Manufacturing Assessment
  • Deborah Johnson: Branch Chief, FDA/CDER/OPQ/ONDP/Division of Lifecycle API
  • Billie Kline: Vertex, Engineering and Materials Science (Drug Substance Process and Crystallization)
  • Ivan Marziano: Pfizer R&D UK Ltd, Crystallization Technology
  • Jeremy Merritt: Lilly, Particle Design Lab, IQ Co-Processed API WG co-lead
  • Sharon Page: Pfizer R&D UK Ltd, GCMC
  • Paresma (Pinky) Patel: Branch Chief, FDA/CDER/OPQ/ONDP/Division of New Drug API
  • Mohan Sapru: Branch Chief, FDA/CDER/OPQ/ONDP/Division of New Drug Products III
  • Luke Schenck: Merck & Co. Inc, Particle Engineering Lab, IQ Co-Processed API WG co-lead
  • Erin Skoda: Branch Chief, FDA/CDER/OPQ/ONDP/Division of Lifecycle API
  • Ramesh Sood: Sr. Scientific Advisor, FDA/ CDER/OPQ/Office of New Drug Products
  • Yihan Wang: University of Maryland, School of Pharmacy
  • Haitao Zhang: Sunovion, Associate Research Fellow, Chemical Process R&D